Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Stock Information for XOMA Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XOMA Corporation

Precigen Reports First Quarter 2024 Financial Results and Business Updates
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
Actym Therapeutics Appoints Thomas Smart as CEO
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th
Precigen Reports Full Year 2023 Financial Results and Business Updates
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th
Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.